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Abstract
Treating bacterial infections can be difficult due to innate or acquired resistance mechanisms, and 
the formation of biofilms. Cyclic lipopeptides derived from fusaricidin/LI-F natural products 
represent particularly attractive candidates for the development of new antibacterial and 
antibiofilm agents, with the potential to meet the challenge of bacterial resistance to antibiotics. A 
positional-scanning combinatorial approach was used to identify the amino acid residues 
responsible for driving antibacterial activity, and increase the potency of these cyclic lipopeptides. 
Screening against the antibiotic resistant ESKAPE pathogens revealed the importance of 
hydrophobic as well as positively charged amino acid residues for activity of this class of peptides. 
The improvement in potency was especially evident against bacterial biofilms, since the lead 
cyclic lipopeptide showed promising in vitro and in vivo anti-biofilm activity at the concentration 
far below its respective MICs. Importantly, structural changes resulting in a more hydrophobic and 
positively charged analog did not lead to an increase in toxicity toward human cells.
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1. Introduction
Pathogens such as Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter sp.[1, 2] 
(collectively called the ESKAPE pathogens) are the leading causes of hospital-acquired 
infections, and are resistant to the most commonly used antibiotics due to their acquisition of 
resistance genes, and their ability to form biofilms; leaving very few therapeutic options.[3, 
4] The discovery of novel antibiotics has historically focused on bacteria growing in a 
planktonic state, however it has recently been indicated that novel therapies addressing 
bacterial infections must account for the presence of biofilms.[5, 6] It has been estimated 
that bacterial biofilms are responsible for approximately 60–80% of all chronic infections.
[7] The important characteristic of chronic biofilm-associated infections is an insensitivity to 
both the host immune response and antimicrobial intervention.[8–11] For example, bacteria 
within a biofilm are up to 1,000 times more resistant to the effect of antibacterial agents than 
the same organism circulating in a planktonic (free swimming) state.[12–14] Poor 
penetration of the drug through the biofilm, slow growth of the biofilm due to nutrient 
limitation, the activation of general stress response pathways, the emergence of a biofilm-
specific phenotype and the presence of persister cells have been suggested as mechanisms of 
biofilm resistance.[15–19] Chronic wounds, such as diabetic ulcers, pressure ulcers and 
venous leg ulcers, are particularly susceptible to the development of biofilm-associated 
infections due to impaired healing properties of patients.[20] These infections are typically 
polymicrobial, with S. aureus and P. aeruginosa most frequently isolated from such 
wounds.[21–23] In addition, A. baumannii has emerged as a significant nosocomial 
pathogen, and is responsible for an increasing number of infections among 
immunocompromised and trauma patients.[24–26] A number of antibiotics have been 
evaluated for the prevention and disruption of biofilms, however few have proven to be 
effective.[27, 28]
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Although limited therapeutic options are presently available, in order to provide effective 
treatments, new and innovative anti-infectives are needed, preferably with novel modes of 
action and/or belonging to novel classes of drugs. To this end, the structurally unique LI-F 
family of natural products, including fusaricidins, represent attractive candidates for the 
discovery and development of new antibacterial agents, capable of treating complicated 
infections caused by multidrug-resistant bacteria, including those found within biofilms.[29–
33] Fusaricidins/LI-Fs are cyclic lipodepsipeptide antifungal antibiotics isolated from 
Paenibacillus sp. Amongst the isolated fusaricidin/LI-F antibiotics, fusaricidin A or LI-F04a 
has been shown to possess the most potent in vitro antimicrobial activity, targeting a variety 
of fungi and Gram-positive bacteria (MICs ranging from 0.78–3.12 μg/mL).[31, 32]
Structural modifications of fusaricidin A/LI-F04a that include incorporation of a simpler 
lipidic tail, and substitution of an ester bond with an amide bond, resulted in comparably 
potent analogs, with improved proteolytic stability under physiologically relevant 
conditions, and greatly decreased nonspecific cytotoxicity.[34] Structures of the most potent 
fusaricidins/LI-Fs synthetic analogs, 1 and 2, are shown in Figure 1. In addition to being 
active against planktonic Gram-positive bacteria, cyclic lipopeptides 1 and 2 showed 
promising activity against bacterial biofilms as well. We have previously demonstrated that 
1 and 2 very efficiently inhibit the growth of S. aureus biofilm in vitro, at concentrations 
corresponding to their MICs, and that depsipeptide 1 reduced the proliferation of 
community-associated MRSA (USA300) in an in vivo porcine wound model.[35] However, 
depsipeptide 1 exhibited significant in vitro toxicity toward human liver and red blood cells.
[34] Although the mode of action of this class of antibacterial peptides is not yet fully 
understood, the bacterial membrane has been suggested as a potential target based on 
analysis of the Bacillus subtilis transcriptome after treatment with the fusaricidin/LI-F 
natural product mixtures.[36] Our initial mechanistic studies showed that 1 and 2 are able to 
depolarize the cytoplasmic membranes of Gram-positive bacteria in a concentration-
dependent manner. However, a lack of correlation between membrane depolarization and 
cell lethality suggested that membrane-targeting activity is not the primary mode of action 
for this class of antibacterial peptides.[37] Due to its improved stability and lower 
cytotoxicity, cyclic lipopeptide 2 may have significant advantages over naturally occurring 
fusaricidin A/LI-F04a and its depsipeptide analogs as a lead structure for the development of 
new antibacterial agents. In addition, amide analogs are synthetically more accessible than 
the parent depsipeptides, allowing for further structural optimization using a combinatorial 
chemistry approach. Indeed, given the 20 amino acid building blocks, even small cyclic 
peptides such as 2 offer enormous diversity, and the potential for discovery of more potent 
analogs. Among combinatorial chemistry strategies, positional scanning synthetic 
combinatorial libraries (PS-SCL) offer a unique and rapid approach for peptide sequence 
optimization.[38–40]
In the pilot study reported herein, we have generated a positional scanning combinatorial 
library of cyclic lipopeptide 2, containing 130,321 cyclic lipopeptides to screen for enhanced 
antibacterial activity. A lead cyclic lipopeptide was identified and assessed for its 
antibacterial/antibiofilm activities and nonspecific toxicity.
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2. Results and discussion
To gain further insight into the amino acid requirements for antibacterial activity and 
toxicity of the fusaricidin/LI-F class of cyclic lipopeptides, and to identify analog(s) with 
improved activities, we prepared a combinatorial library of cyclic lipopeptide 2. Cyclic 
lipopeptide 2 was used as a model compound due to its low nonspecific toxicity, promising 
antibacterial/antibiofilm activities, and ease of synthesis.
2.1. Library design and synthesis
The general strategy for cyclic lipopeptide combinatorial library preparation and library 
deconvolution is outlined in Scheme 1. The cyclic lipopeptide synthetic combinatorial 
library was generated by the process of divide, couple and recombine (tea bag“ method) 
using a previously developed Fmoc SPPS chemistry.[34, 41, 42] In brief, our synthetic 
strategy included attachment of the C-terminal amino acid Fmoc-D-Asp5-OAllyl to a PEG-
based amide resin via the side chain, use of a combination of orthogonal protecting groups, 
stepwise solid-phase assembly of a linear precursor, attachment of a lipidic tail followed by 
coupling of the N-terminal Fmoc-Dap1(Mtt)-OH and on-resin cyclization. To maintain the 
same order of D- and L-amino acids as they appear in the sequences of the fusaricidin/LI-F 
natural products in the synthesized cyclic lipopeptides, D-Val2, D-Thr4, and D-Ala6 were 
replaced with D-amino acid mixtures, whereas L-Val3 was similarly replaced with an L-
amino acid mixture. Fmoc deprotection, amino acid coupling reactions and final cyclization 
steps were monitored by a ninhydrin colorimetric test.[43, 44] As depicted in Scheme 1, four 
sets of 19 cyclic lipopeptide sub-libraries (Cys is omitted because of its propensity to form 
disulfide bonds) were prepared. The first set of 19 sub-libraries had specifically defined 
amino acids in position 4 of the sequence (one of the 19 commercially available D-amino 
acids), whereas the remaining three positions consisted of mixtures of the 19 D- or 19 L-
amino acids. The next set of cyclic peptide sub-libraries were defined by the amino acid in 
position 3 (one of the 19 commercially available L-amino acids), and the remaining 
positions contained all possible amino acid combinations. This process was thus repeated for 
the remaining amino acid residues. Variable positions were incorporated by coupling of a 
mixture of 19 Fmoc-protected amino acids in predetermined molar ratios to compensate for 
different coupling rates.[42] Protocols for the removal of Allyl and Mtt protecting groups, 
on-resin cyclization, and cleavage of cyclic lipopeptide mixtures from the resin were 
identical to those previously described for the synthesis of cyclic lipopeptide 2.[34, 37] 
Using a PS-SCL approach, we generated a combinatorial library containing 130,321 cyclic 
lipopeptides.
2.2. Library screening and assessment antibacterial and antibiofilm activities of individual 
peptides
To demonstrate the feasibility of the PS-SCL approach to identify novel cyclic lipopeptides 
with improved antibacterial and antibiofilm activities, we screened the cyclic lipopeptide 
library for activity against the ESKAPE pathogens. Screening assays were performed 
according to standard microbroth dilution methods, using a tier of three different 
concentrations (100, 50 and 25 μg/mL) in 96-well plates.[45, 46] As indicated from 
screening assays, Figure 2, the sequences of cyclic lipopeptides for activity against both 
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Gram-positive and Gram-negative bacteria were identified to contain neutral and positively 
charged Lys and/or Arg amino acids. Therefore, we synthesized the nine peptides with 
sequences shown in Figure 1. Cyclic lipopeptides 1, 2 and linear lipopeptide 13 were used 
for comparison purposes.
All individual peptides 1–13 were synthesized as described previously.[34, 37] The 
antibacterial in vitro activity of peptides 1–13 against ESKAPE pathogens was assessed in 
an identical fashion as above, and those data are shown in Table 1. Cyclic lipopeptide 3 was 
active against all ESKAPE pathogens at 110 μM (100 μg/mL); whereas at a much lower 
concentration of 28 μM (25 μg/mL), this peptide exhibits antibacterial activity against VRE, 
MRSA and A. baumannii. In addition, cyclic lipopeptide 3 was active against MRSA and P. 
aeruginosa at 22 μM (20 μg/mL) and 55 μM (50 μg/mL) respectively. In comparison to 
depsipeptide 1 and parent amide 2, these data demonstrate significant extension of the 
antibacterial spectrum of 3.
As shown in Table 1, depsipeptide 1 was active against VRE and MRSA at concentrations 
of 30 μM (25 μg/mL) and 12 μM (10 μg/mL), respectively, whereas amide 2 at 62 μM (50 
μg/mL) showed activity only against MRSA. Among other synthesized cyclic lipopeptides, 
4 exhibits activity against VRE, MRSA and A. baumannii at 36 μM (35 μg/mL) and against 
K. pneumoniae at 52 μM (50 μg/mL). No activity against P. aeruginosa and E. cloacae was 
observed for this peptide at concentrations ≤104 μM (100 μg/mL), as shown in Table 1. All 
other cyclic lipopeptides 5–12 did not show appreciable antibacterial activity against the 
tested ESKAPE pathogens. Possible synergy of multiple peptides present in mixtures (76 
mixtures each composed of 6,859 cyclic lipopeptides) containing these peptides may explain 
the observed antibacterial activity for mixtures, as well as loss of activity in the case of the 
individual peptides,[47, 48] More accurate identification of amino acids that drive 
antibacterial activity of the described cyclic lipopeptides can be achieved by synthesis and 
screening of a less complex, second generation PS-SCL composed only of the identified 
hydrophobic and positively charged residues, thus reducing the possibility for synergistic 
effect. Quite interestingly, an increase in a peptide’s cationicity, as exemplified by peptides 
7 and 10, did not improve antibacterial activity. This observation is consistent with the 
literature, and suggests that the balance of charge and hydrophobicity is delicate, and has to 
be determined for each class of antimicrobial peptide.[49] Taking into consideration that 
peptide 3 exhibits the most broad and potent antibacterial activity in this series of cyclic 
lipopeptides, we selected it for further studies.
In the case of cyclic lipopeptide 3, the greatest improvement in activity was observed against 
bacterial biofilms. The in vitro ability of peptides 1–3 to decrease the number of cells within 
biofilms, and disrupt mature 2-day old biofilms formed by MRSA and P. aeruginosa, was 
assessed using flow cell chamber methodology, as described previously.[50] In each 
experiment, all cells within biofilms were stained green with the fluorescent dye Syto-9, and 
dead cells were stained red with propidium iodide (merge shown as yellow to red) for 
subsequent visualization using confocal microscopy. Representative confocal microscopy 
reconstructed images of S. aureus and P. aeruginosa biofilms untreated or treated with 
cyclic lipopeptodes 1–3 are shown in Figure 3. The most potent activity against biofilms 
formed by both organisms was observed for cyclic lipopeptide 3. Treatment with 3 at a 
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concentration of 4 μg/mL resulted in complete inhibition of biofilm formation, as well as 
complete eradication of mature biofilms formed by both bacterial species. As shown in 
Figure 3, depsipeptide 1 at 4 μg/mL was comparably effective in prevention and eradication 
of Gram-positive (S. aureus) biofilms, whereas this peptide was slightly less effective 
against Gram-negative (P. aeruginosa) biofilms. Conversely, the parent amide 2 at the same 
concentration was able to prevent biofilm formation by S. aureus and P. aeruginosa, but was 
unable to completely eradicate existing biofilms of these two organisms. Even though amide 
2 did not eradicate mature S. aureus biofilms, it did substantially trigger biofilm cell death 
under these conditions, as shown by the bacterial uptake of propidium iodide that stains cells 
red (merged with Syto-9 shows as yellow) in Figure 3. The observed improved antibiofilm 
activity of 3 is consistent with its activity against bacteria in a planktonic state and can be 
attributed to an increase in the peptide’s overall hydrophobicity and cationicity relative to 
the parent peptide 2. The more hydrophobic and cationic cyclic lipopeptide 3 more 
efficiently penetrates into bacterial biofilm matrices and consequently more effectively 
reduces bacterial viability.
We and others have shown that substitution of D-Ala6 residue with either Gly6 or L-Ala6 
causes a significant loss in antimicrobial activity of the fusaricidin/LI-F class of cyclic 
lipopeptides.[34, 51] However, the fact that cyclic lipopeptide 3 with D-Lys in position 6 
exhibits improved antibacterial activity, suggests that incorporation of a positively charged 
amino acid into the sequence of fusaricidin/LI-F cyclic lipopeptides is well tolerated. This 
finding is of particular practical significance for further optimization of cyclic lipopeptide 3 
and related peptides, considering that the net charge, and the number of positively charged 
residues, has been strongly correlated with biological activity for antimicrobial peptides.[52, 
53] Predictably, control linear peptide 4 did not show activity against any of the ESKAPE 
bacteria, Table 1, supporting our previous study that indicated the importance of the cyclic 
structure for antibacterial activity.[34]
2.3. In vitro assessment of the potential for resistance development to 3
Serial exposure of bacteria to antibacterial agents can be used to assess the propensity of an 
organism to develop resistance.[54] Therefore, we investigated the potential of 3 to select 
for resistance by initially passaging bacteria at sub-inhibitory concentrations, and then 
increasing this by 2-fold each day. MRSA and P. aeruginosa were selected for these studies 
as representative Gram positive and Gram-negative species because of the promising 
inhibitory activity demonstrated thus far. In addition, these strains are clinical isolates, and 
drug resistance amongst these organisms is wide-spread, substantially limiting available 
treatment options. Vancomycin and ciprofloxacin were used as reference antibiotics. After 
eight passages, the MIC of 3 increased approximately 8-fold against MRSA and P. 
aeruginosa, Figure 4. In contrast, under the same experimental conditions, MICs obtained 
for vancomycin and ciprofloxacin increased 64-fold in both tested bacteria. These findings 
demonstrate limited ability of our clinical, broadly drug-resistance isolates, to develop 
resistance towards the cyclic lipopeptides, compared to clinically relevant antibiotics. As 
such, this indicates the potential for very low rates of resistance development to 3, and 
related cyclic lipopeptides.
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2.4. Cytotoxicity
It has been well established in the literature that the net positive charge (which facilitates 
interaction with anionic phospholipids in the bacterial membrane), conformational flexibility 
(allowing transition from a given peptides solution conformation to its active conformation), 
hydrophobicity and amphipathicity (required for membrane penetration) are major factors 
that affect the activity of antimicrobial peptides.[55–57] However, the enhancement of 
hydrophobicity and cationicity can decrease selectivity between bacterial and human cells.
[57] Incorporation of more hydrophobic amino acids such as Leu and Ile, and positively 
charged Lys into the cyclic lipopeptide sequence, increased its overall hydrophobicity and 
net positive charge. In the case of cyclic lipopeptides 1–3, the relative overall 
hydrophobicity order was 2<1<3, as indicated by their HPLC retention times (15.1, 15.8 and 
16.9 min, respectivly). Since 3 is the most hydrophobic cyclic lipopeptide in the series, as a 
measure of toxicity, the hemolysis of human erythrocytes and toxicity towards BJ human 
skin fibroblasts induced by 3 was assessed.
Hemolytic activity was determined against human erythrocytes (0.5 % in PBS), Figure 5. 
PBS and 1 % Triton X-100 were used as controls for 0 and 100 % hemolysis, respectively. 
Despite the increase in hydrophobicity and positive charge in comparison to 1 or 2, cyclic 
lipopeptide 3 did not show hemolytic activity at the highest tested concentration of 564 μM 
(512 μg/mL), Figure 5. In comparison, low hemolytic activity was reported for cyclic 
lipopeptide 2, as no appreciable hemolysis was observed at a concentration of 320 μM (260 
μg/mL), whereas cyclic lipodepsipeptide 1 was shown to be highly hemolytic at a 
concentration of 155 μM (128 μg/mL).[34] DMSO (1% v/v final concentration) used to 
solubilize cyclic lipopeptide 3 did not cause hemolysis under the conditions described in the 
Experimental Section.
Toxicity of cyclic lipopeptides 1–3 toward human BJ cells is shown in Figure 6. The known 
cytotoxic drug doxorubicin (Adriamycin) and 20% DMSO were used as positive and 
negative controls in these assays. Low toxicity of 2 and 3 was observed against BJ cells; 
with inordinately high concentrations required for both peptides 2 (250 μM, 203 μg/mL) and 
3 (250 μM, 227 μg/mL) to induce a significant loss in cell viability. In contrast, no viable 
cells were detected in cultures after incubation with depispeptide 1 at a concentration of 150 
μM (124 μg/mL). This is consistent with our previous finding, showing lower cytotoxicity of 
cyclic lipopeptides (amide analogs) in comparison to their depsipeptide counterparts.[34]
2.5. In vivo study
The ability of cyclic lipopeptide 3 to reduce the proliferation of A. baumannii was assessed 
in a porcine model of deep partial thickness wound, Figure 7. Wound infections caused by 
this pathogen are difficult to treat due to a high level of resistance to multiple antibiotics and 
its capacity to form a biofilm.[58] In addition, the recent reports indicated an increasing 
identification of A. baumannii from wound, skin and soft-tissue infections,[24, 25] with a 
higher incidence rate among hospitalized patients and injured military service members.[26] 
Swine were chosen for this experiment due to the morphological and biochemical similarity 
with human skin.[59]
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Wounds were inoculated with 25 μL of 106 CFU/mL of A. baumannii immediately after 
treatment application and covered with a polyurethane film dressing to allow for biofilm 
formation as previously described.[60] Infected wounds were treated with cyclic lipopeptide 
3 at concentrations of 5.5, 11, 22 mM (5, 10, and 20 mg/mL), DMSO solutions. As shown in 
Figure 6, peptide 3 reduced the number of A. baumannii in wounds in a concentration-
dependent manner. At the highest tested concentration of 22 mM (20 mg/mL), a decrease of 
approximately 3 log-units in the number of viable A. baumannii in comparison to untreated 
wound was observed, indicating an antimicrobial effect of cyclic lipopeptide 3 on A. 
baumannii in vivo. The same effect on A. baumannii was observed upon wound treatment 
with silver sulfadiazine (1% cream), widely used to prevent and treat wound infections in 
patients. Importantly, cyclic lipopeptide 3 at 22 mM (20 mg/mL) does not exhibit any 
observable adverse effects, which is consistent with the low toxicity observed for this 
peptide in the in vitro experiments.
3. Conclusion
In summary, we have demonstrated that modifying the amino acid sequences of cyclic 
lipopeptides belonging to the fusaricidin/LI-F class of antimicrobial peptides seemingly 
leads to analogs with improved anibacterial/antibiofilm activities and markedly decreased 
nonspecific toxicity. The sequence of cyclic lipopeptide 2 was modified in a positional 
scanning format, allowing for the rapid identification of amino acid residues responsible for 
driving antibacterial activity at each position. Of note, screening against the ESKAPE 
pathogens revealed the importance of hydrophobic as well as positively charged amino acid 
residues for activity of this class of antibacterial peptides. An increase in overall 
hydrophobicity of cyclic lipopeptides, and their net positive charge, resulted in improved 
antibacterial activity. This improvement is particularly important for activity against 
bacterial biofilms, as the lead peptide 3 showed potent broad-spectrum antibiofilm activity. 
In contrast to the parent cyclic lipopeptide 2, peptide 3 at a concentration of 4.4 μM (4 
μg/mL) effectively inhibited biofilm formation and was able to fully eradicate mature 
biofilms formed by both MRSA and P. aeruginosa. In addition, a serial passage in vitro 
resistance development study shows that peptide 3 has a low propensity to select for 
resistance compared with vancomycin and ciprofloxacin. Promising in vivo antibacterial 
activity of 3 was demonstrated by prevention of A. baumannii growth in a porcine model of 
deep partial thickness wounds. Importantly, structural changes resulting in an increase of 
overall hydrophobicity and cationicity did not lead to increased nonspecific toxicity. By 
identifying peptide 3 possessing amino acid sequences that are not found in either the parent 
peptide 2, or in any of the fusaricidin/LI-F natural products, we have demonstrated that our 
approach may go beyond fusaricidin/LI-F natural product sequences in the discovery of 
novel and more potent antibacterial peptides of this class.
Clearly, our findings warrant further investigation of the fusaricidin/LI-F class of cyclic 
lipopeptide structure-activity relationship and their modification to find the optimal balance 
between antibacterial activity and toxicity. Synthesis of additional cyclic lipopeptides based 
on our screening assay against ESKAPE bacteria, and assesment of their antibacterial/
antibiofilm activities and toxicity, is currently underway by our group.
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4. Experimental section
4.1. Materials and methods
TentaGel XV RAM resin was obtained from Rapp Polymere, GmbH. (Tuebingen, 
Germany). Fmoc-protected amino acids and coupling reagents (HOBt, HBTU, PyBOP) were 
purchased from Chem-Impex (Wood Dale, IL, USA). N-methylmorpholine, triethylamine 
and Pd(PPh3)4 was purchased from Sigma-Aldrich (St. Louis, MO, USA). All solvents were 
purchased from Sigma–Aldrich, and were analytical reagent grade or better. Individual 
peptides were synthesized on a PS3 automated peptide synthesizer (Protein Technologies 
Inc., Tucson, AZ, USA). Mass spectrometry was performed on MALDI-TOF Voyager-DE 
STR (Applied Biosystems, Foster City, CA, USA) in reflector mode using α-cyano-4-
hydroxycinnamic acid as a matrix and positive mode. Analytical RP-HPLC analyses and 
peptide purifications were performed on 1260 Infinity (Agilent Technologies, Santa Clara, 
CA, USA) liquid chromatography systems equipped with a UV/Vis detector. For analytical 
RP-HPLC analysis, a C18 monomeric column (Grace Vydac, 250 × 4.6 mm, 5 mm, 120 Å), 
1 mL/min flow rate, and an elution method with a linear gradient of 2–98 % B over 30 min, 
where A is 0.1 % TFA in H2O, and B is 0.08 % TFA in CH3CN were used. For peptide 
purification, a preparative C18 monomeric column (Grace Vydac, 250 × 22 mm, 10 mm, 
120 Å) was used. Elution method was identical to the analytical method except for the flow 
rate, which was 19 mL/min. Cytotoxicity assays were analyzed on a Synergy H4 microplate 
reader (BioTek, Winooski, VT, USA). The ESKAPE pathogen isolates (Vancomycin-
Resistant E. faecium strain USF-1449, Methicillin-Resistant S. aureus strain CBD-635, K. 
pneumoniae strain USF-1433, A. baumannii strain USF-1403, P. aeruginosa strain 
USF-1423 and E. cloacae strain USF-1454) used for MIC and resistance testing have been 
described by us previously.[61] A. baumannii (ATCC 19606) used in the in vivo study and 
human skin fibroblasts BJ (ATCC CRL-2522) cells were purchased from American Type 
Culture Collection (ATCC, Manassas, VA, USA). S. aureus (MRSA, #SAP0017) and P. 
aeruginosa (reference strain PA14) used in the flow cell experiments were obtained from the 
UBC collection. Dehydrated culture media and polystyrene plates (BD 353072 Falcon) used 
for antimicrobial and human cell toxicity assays were purchased from Becton Dickinson 
(Franklin Lakes, NJ, USA). Microscopy was performed using a Leica DMI 4000 B wide-
field fluorescence microscope (Leica Microsystems Inc., Buffalo Grove, IL, USA). Control 
antibiotics were purchased from Sigma–Aldrich. Human red blood cells (hRBCs) were 
purchased from Innovative Research (Novi, MI, USA). A young female specific-pathogen-
free Yorkshire pig was purchased from Looper Farms (NC, USA). Tegaderm polyurethane 
film dressing was purchased from 3M Health Care (St. Paul, MN, USA).
4.2. General procedure for peptide synthesis and purification
Cyclic lipopeptide PS-SCL and individual peptides 1–13 were synthesized on amide 
TentaGel XV RAM resin (substitution 0.26 mmol/g, 0.025 mmol scale) using standard 
Fmoc solid-phase chemistry as reported previously.[34, 37] In all cases the solid-phase 
synthesis started by attaching C-terminal Fmoc-D-Asp-OAllyl via side chain to the resin 
using HBTU/HOBt/NMM protocol. The same coupling protocol was used throughout, 
including coupling of the lipidic tail (Fmoc-12-aminododecanoic acid, 1.5 eq). In the case of 
depsipeptide 1, Alloc-D-Ala-OH (4 eq) was coupled via ester bond to the hydroxyl group of 
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Fmoc-Thr using N,N′-diisopropylcarbodiimide (DIC, 4 eq.) and 4-dimethylaminopyridine 
(DMAP, 1 eq) coupling reagents in CH2Cl2. PS-SCL and peptides 2–13 were prepared by 
coupling Fmoc-Dap(Mtt)-OH instead of Fmoc-Thr-OH using the same coupling protocol as 
above. Selective removal of Allyl and Alloc protecting groups was performed by treatment 
of peptidyl-resin precursors with borane dimethylamine complex (4 eq), followed by 
addition of Pd(PPh3)4 (0.1 eq) in CH2Cl2 under argon. Mtt was selectively removed under 
mild acidic conditions (1% trifluoroacetic acid in CH2Cl2, 30 min). Solid-phase cyclization 
of linear precursors was carried out in a manual reaction vessel overnight using PyBOP/
HOBt/DIEA (2:2:6 eq) in DMF. The conversion of the lipid tail amino group into the 
desired guanidino group was achieved by removal of the Fmoc protecting group using 
standard piperidine deprotection protocol and treatment of the peptidyl-resin with N,N′-di-
Boc-N″-triflylguanidine (5 eq) and triethylamine (5 eq) in DCM as described previously.[62] 
The final purity of synthesized peptides 1–13 was confirmed by analytical RP-HPLC, LC 
ESI MS and MALDI TOF MS, and was ≥ 95% in all cases.
4.3. Screening of cyclic lipopeptide PS-SCL and assessment of antibacterial activities of 
peptides 1–13
Screening of cyclic lipopeptide PS-SCL for activity against the ESKAPE pathogens was 
performed using three different concentrations (100, 50, and 25 μg/mL) in sterile 96-well 
flat-bottomed polystyrene plates according to the Clinical and Laboratory Standards Institute 
(CLSI) guidelines.[45] Müller–Hinton broth (MHB) without dilution was used in this 
experiment. The cyclic lipopeptide PS-SCL was solubilized in DMSO and appropriate 
dilutions were made in media to a final 1% DMSO concentration (v/v). Controls on each 
plate were media without bacteria, bacterial inoculum without antimicrobials added, and 
bacterial inoculum containing methicillin, vancomycin, nisin, colistin and bacitracin. 
Assessment of activities of peptides 1–13 against ESKAPE bacteria was completed in an 
identical fashion to that described above. All experiments were performed in triplicate.
4.4. Hemolytic activity
Human red blood cells (hRBCs) were diluted in PBS to 1%. Cyclic lipopeptide 3 was 
dissolved in 10% DMSO/H2O (v/v) solvent mixture to concentrations of 8.8–1128 μM (8–
1024 μg/mL). In each well of a clear, flat-bottom 96-well plate, 50 μL of hRBCs were 
placed, followed by addition of 50 μL of cyclic lipopeptide solution, to a final peptide 
concentration of 4.4–564 μM (4–512 μg/mL). Assays were performed in triplicate, and each 
experiment was repeated twice. To determine the potential effect of DMSO on hemolytic 
activity, controls containing 10 % DMSO in H2O (v/v) were added to the assay setup. As a 
positive control, 50 μL Triton X-100 in H2O was used at a final concentration of 1 % (v/v). 
As a negative control, 50 μL of PBS was used. Plates were incubated for 1 h at 37 °C. To 
each well 100 μL of PBS was added, and the plates were centrifuged for 10 min at 1000 g. 
Supernatants (150 μL) were transferred to a new plate, and absorbance at 405 nm was 
measured. No effect of 10% DMSO in H2O on hemolysis of hRBCs was observed. The 
degree of hemolysis of the cyclic lipopeptides was expressed in percent relative to the 
hemolysis caused by Triton-X.
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4.5. Cytotoxicity
Cytotoxicity of peptides 1–3 was determined using Cell Titer-Glo Luminescent Cell 
Viability Assay (Promega). Assays were performed in flat-bottom polystyrene 96-well 
plates with 10,000 BJ cells (ATCC CRL-2522) per well grown in EMEM containing 10% 
FBS, and 5% penicillin/streptomycin (v/v). After overnight incubation at 37°C in a 
humidified atmosphere with 5% CO2, media was removed, and replaced with fresh media 
with 2% FBS containing peptides 1–3 in a concentration range of 0.5–500 μM. Peptides 1–3 
were dissolved in DMSO, and appropriate dilutions were made in buffer to a final 
concentration of 1% DMSO (v/v). Plates were again incubated at 37°C in a humidified 
atmosphere with 5% CO2. As a control, 10 μM doxorubicin and 20% DMSO in H2O were 
used. After incubation for 48 and 72 h, respectively, media was removed, and 100 μL PBS 
buffer added, followed by 100 μL of Cell Titer-Glo Reagent. Plates were incubated for 
further 10 min at room temperature (protected from light), before luminescence readout.
4.6. Flow cell experiments and biofilm imaging by confocal microscopy
For inhibition studies, Pseudomonas aeruginosa PA14 and Staphylococcus aureus MRSA 
(clinical isolate #SAP0017) biofilms were grown in BM2 minimal glucose medium for 72 h, 
with and without the addition of cyclic lipopeptides 1–3 (final concentration of 4.4 μM (4 
μg/mL) at 37°C in flow chambers as previously described.[50] In eradication studies, 
bacteria were allowed to develop structured biofilms for 2 days prior to peptide treatment for 
24 h. Silicone tubing (VWR, 0.062 in ID by 0.125 in OD by 0.032 in wall) was autoclaved, 
and the system was assembled and sterilized by pumping a 0.5% hypochlorite solution 
through the system at 6 rpm for 30 min using a Watson Marlow 205S multi-channel 
peristaltic pump. The system was then rinsed with sterile water and medium for 30 min 
each. Flow chambers were inoculated by injecting 400 μL of an overnight culture diluted to 
an OD600 of 0.05. After inoculation, chambers were left without flow for 2 h to allow 
bacteria to adhere to the surface of the flow cell chambers, after which medium was pumped 
through the system at a constant rate of 0.5 rpm (2.4 mL/h). Biofilm cells were stained using 
the LIVE/DEAD BacLight Bacterial Viability kit (Molecular Probes, Eugene, OR) prior to 
microscopy experiments. A ratio of SYTO-9 (green fluorescence, live cells) to propidium 
iodide (PI) (red fluorescence, dead cells) of 1:5 was used. Microscopy was done using a 
confocal laser scanning microscope (Olympus, Fluoview FV1000) and three-dimensional 
reconstructions were generated using the Imaris software package (Bitplane AG).
4.7. Serial passage experiment
Serial passage was initiated from overnight cultures of MRSA CBD-635 and P. aeruginosa 
USF-1423 grown in MHB to exponential growth phase and added to a fresh medium 
containing cyclic lipopeptide 3 or the controls vancomycin and ciprofloxacin at 
concentrations corresponding to ½ MICs. Final bacterial concentrations were approximately 
106 CFU/mL. The bacteria were incubated overnight at 37°C and an aliquot was transferred 
to a new tube with 2 fold increased concentration of 3 or control antibiotics. The process 
was repeated for 8 passages. The MIC was determined at each step as described above.
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4.8. Antibacterial activity in in vivo wound infection model
Wounding and infection—A young female specific-pathogen-free pig was used. The 
animal was fed a non-antibiotic chow ad libitum before the study, fasted overnight before 
the procedures, and housed individually in our USDA-compliant animal facilities. The 
experimental protocol was approved by the University of Miami Institutional Animal Care 
and Use Committee, and all the procedures followed the federal guidelines for the care and 
use of laboratory animals. Methods for the animal preparation and wounding are described 
previously.[23, 63–65] Briefly, the flank and the back of experimental animals were prepped 
on the day of the experiment. Animals were anesthetized and partial thickness wounds were 
made on the paravertebral area using a modified electrokeratome set at 0.5 mm deep × 10 
mm × 7 mm.[63] The wounds were separated from one another by approximately 4–6 cm 
areas of unwounded skin. Wounds were inoculated with 25 μL of 106 CFU/mL of A. 
baumannii (ATCC 19606). Wounds were treated within 20 min (after inoculation) with 200 
μL of peptide 3 (5, 10 and 20 mg/mL; 5.5, 11, 22 mM), vehicle (DMSO) and silver 
sulfadiazine (1% ointment, 150–200 mg/wound).. Control wounds were infected and no 
treatment was applied. All wounds, including control, were covered with polyurethane film 
dressing (Tegaderm) to maintain a moist environment, promote biofilm formation and 
prevent any cross-contamination between wounds.[60]
Bacterial recovery—Three wounds from each treatment group were cultured 
quantitatively using a modified scrub technique.[60] Each wound was encompassed by a 
sterile surgical grade steel cylinder (22 mm outside diameter), and bacteria were collected 
by scrubbing the wound area with a sterile Teflon spatula into 1 mL of sterile phosphate 
buffer saline. Serial dilutions were made and plated using a Spiral Plate System, and Leeds 
selective media was used to determine CFUs in the scrub solution collected from each 
wound. Plated bacteria were incubated aerobically for 48 h at 37°C. CFUs were determined 
by the standard colony counting method.
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HIGHLIGHTS
• Positional-scanning combinatorial library of cyclic lipohexapeptides was 
prepared.
• Analogs with improved antibacterial activities were identified.
• The improvement in activity was especially evident against bacterial biofilms.
• Hydrophobic and positively charged amino acids are crutial for activity.
• Resulting structural changes did not lead to an increase in nonselective toxicity.
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Figure 1. 
Sequences of cyclic lipopeptides 1–12 and control lipopeptide 13.
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Figure 2. 
Screening of cyclic lipopeptide positional scanning-synthetic combinatorial library for 
activity against the ESKAPE pathogens. Nineteen amino acids were tested for activity at 
each of the four varying positions. A = R2; B = R3; C = R4; and D = R6. The height for each 
individual bar is determined by dividing 100 μg/mL (the maximum concentration tested) by 
the individual MIC for each agent against the respective pathogen. Libraries are then given a 
scaled score for each pathogen, and these are then stacked to determine the amino acid that 
displays the broadest activity, at the lowest concentration.
Bionda et al. Page 19
Eur J Med Chem. Author manuscript; available in PMC 2017 January 27.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. 
Cyclic lipopeptides prevented biofilm formation and eradicated existing biofilms of Gram-
negative and Gram-positive bacterial pathogens. Inhibition of biofilm formation was tested 
by immediately adding 4.4 μM (4 μg/mL) of each cyclic lipopeptide 1–3 into the flow-
through medium of the flow cell apparatus, and subsequently monitoring biofilm formation 
for a total of 3 days. Eradication experiments involved growing biofilms untreated for two 
days before the addition of peptides into flow-through medium. After 3 days, all bacteria 
were stained green with stain Syto-9, while dead-bacteria were stained red with propidium 
iodide (merge shown as yellow to red) prior to confocal imaging. Each panel shows 
reconstructions from the top in the large panel and sides in the right and bottom panels (xy, 
yz and xz dimensions). (A to C) shows inhibition of biofilm formation. (D–F) shows 
eradication of preformed biofilms. (G) shows untreated bacteria.
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Figure 4. 
Resistance acquisition during serial passaging in the presence of sub-MIC levels of 
antimicrobials. (A) MRSA CBD-635 and (B) P. aeruginosa USF-1423. MICs are: a) cyclic 
lipopeptide 3, 22 μM (20 μg/mL) for S. aureus and 55 μM (50 μg/mL) for P. aeruginosa; b) 
vancomycin, 7 μM (10 μg/mL); c) ciprofloxacin, 30 μM (10 μg/mL). The figure is 
representative of three independent experiments.
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Figure 5. 
Hemolytic activity of cyclic lipopeptide 3. 100% hemolysis was determined by incubating 
hRBCs with 1% Triton X.
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Figure 6. 
Toxicity of cyclic lipopeptides 1–3 toward BJ human skin fibroblasts. Doxorubicin and 
DMSO were used as positive controls. 1 (■), 2 (□), 3 ( ).
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Figure 7. 
Effect of 3 on A. baumannii 19606 in vivo using a deep partial thickness porcine wound 
model. A. baumannii CFUs were determined from porcine wounds 24h post infection and 
topical treatment with 3 (n=3). Silver sulfadiazine was used as 1% cream.
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Scheme 1. 
Positional scanning synthetic combinatorial library of cyclic lipopeptides. Each set contains 
19 separate mixtures. (X) represents position composed of a mixture of 19 amino acids 
(redox-sensitive Cys is omitted). (Y) represents position defined with an individual amino 
acid.
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